Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ALPG | P10696 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.45 |
| ▸ | TDP2 | O95551 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30886771 | 1.00 | PDE7A (0.51) | PDE7ASMN1; SMN2HSD17B10SLC6A2SLC6A4 | |
| SCHEMBL11202237 | 0.85 | PDE7A (0.49) | PDE7ASMN1; SMN2HSD17B10SLC6A2SLC6A4 | |
| SCHEMBL4910926 | 0.81 | PDE7A (0.49) | PDE7ASMN1; SMN2HSD17B10SLC6A2SLC6A4 | |
| SCHEMBL8941930 | 0.81 | ALDH1A1 (0.50) | PDE7ASMN1; SMN2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10127002 | 0.80 | TSHR (0.56) | PDE7AHSD17B10SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3384869 | 0.79 | PDE7A (0.58) | PDE7ASMN1; SMN2HSD17B10SLC6A2SLC6A4 | |
| SCHEMBL1491752 | 0.79 | PDE7A (0.39) | PDE7ASMN1; SMN2MAPTALDH1A1TDP1 | |
| SCHEMBL11413362 | 0.79 | TSHR (0.53) | PDE7ASMN1; SMN2HSD17B10MAPTALDH1A1 | |
| SCHEMBL2061399 | 0.79 | ATM (0.58) | PDE7AMAPTALDH1A1TDP1KMT2A | |
| SCHEMBL2847249 | 0.79 | PDE7A (0.57) | PDE7ASMN1; SMN2MAPTALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021057867-A1 | CLASS OF CDK INHIBITOR BASED ON ORGANIC ARSINE, PREPARATION METHOD AND APPLICATION THEREOF | 中国科学院上海有机化学研究所 | 2021-04-01 | — | — | WO | disclosed |
| WO-2021057867-A1 | CLASS OF CDK INHIBITOR BASED ON ORGANIC ARSINE, PREPARATION METHOD AND APPLICATION THEREOF | 中国科学院上海有机化学研究所 | 2021-04-01 | — | — | WO | disclosed |
| WO-2016199020-A1 | PROCESS FOR PREPARATION OF CERITINIB | DR. REDDY'S LABORATORIES LIMITED (IN) | 2016-12-15 | — | — | WO | disclosed |
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. | 2016-05-19 | — | — | US | disclosed |
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. | 2016-05-19 | — | — | US | disclosed |
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. | 2016-05-19 | — | — | US | disclosed |
| EP-2257637-B1 | METHODS OF CHEMOTYPE EVOLUTION | SUNESIS PHARMACEUTICALS INC (US) | 2015-09-23 | — | — | EP | disclosed |
| CN-104592068-A | One-pot synthesis method of anticancer drug ceritinib intermediate 1-(isopropylsulfonyl)-2-nitrobenzene | CHANGZHOU BAIAOWEI BIOTECHNOLOGY CO LTD | 2015-05-06 | — | — | CN | disclosed |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. | 2013-05-30 | — | — | US | disclosed |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. | 2013-05-30 | — | — | US | disclosed |
| WO-2011140338-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140338-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110118126-A1 | METHODS OF CHEMOTYPE EVOLUTION | SUNESIS PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118126-A1 | METHODS OF CHEMOTYPE EVOLUTION | SUNESIS PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | disclosed |
| WO-2009120795-A1 | METHODS OF CHEMOTYPE EVOLUTION | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009032694-A1 | AMINO SUBSTITUTED PYRIMIDINE, PYROLLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS AND IN TREATING PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | DANA FARBER CANCER INSTITUTE (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032703-A1 | 2- (HET) ARYLAMINO-6-AMINOPYRIDINE DERIVATIVES AND FUSED FORMS THEREOF AS ANAPLASTIC LYMPHOMA KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | WO | disclosed |
| US-4239688-A | Herbicidal N-(haloacetyl)-N-(N'-methylenepyrrolidonyl-2-mercaptoalkylanilines | GAF CORPORATION (US) | 1980-12-16 | — | — | US | disclosed |
| US-4203901-A | Process for making N-(N'-methylenepyrrolidonyl)-2-substituted anilines | GAF CORPORATION (US) | 1980-05-20 | — | — | US | disclosed |
| US-4202821-A | N-(N'-Methylenepyrrolidonyl)-2-substituted anilines | GAF CORPORATION (US) | 1980-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | EGFR, ERBB2, BRCA1 | PDE7A 1540/4885SMN1; SMN2 1829/4885HSD17B10 2633/4885 |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | EGFR, ERBB2, BRCA1 | PDE7A 1540/4885SMN1; SMN2 1829/4885HSD17B10 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.